Skip to main content
Equibles
EIKN logo

EIKN · Eikon Therapeutics, Inc.

Track EIKN — free

Use EIKN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EIKN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.94 -0.27 (-2.93%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$484.24M
Shares
54.17M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.94 Open$9.28 Day$8.79–9.56 Available close range$8.36–16.26 Avg vol 30d491K Short int5.3M · 9.7% float · 10.3d Short vol53% DataFeb 2026–Sep 2026 Filing10-Q · Aug 13

The closing range uses available history since Feb 5, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$531.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,800.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
9.7%
Latest settlement · 10.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 50-day avg −14%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 7%
near low
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −24%
trailing
Relative strength −42%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+48% holders QoQ · +37 funds added
Insider flow Accumulating
Net +$1.0M over 90 days · 0% sells
Short interest Rising
9.75% of float · ▲ +26.3% MoM · 10.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
77 holders — 13F breadth
Squeeze score 78
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −49%
past year
ATR 10.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
3 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−14% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
7% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+48% holders QoQ · +37 funds added
Insider flow Accumulating
Net +$1.0M over 90 days · 0% sells
Short interest Rising
9.75% of float · ▲ +26.3% MoM · 10.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
77 holders — 13F breadth
Price context
position in its available closing range
Range low $8 Now $9 · 7% Range high $16
vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EIKN
Eikon Therapeutics, Inc.
this stock
$484.24M — — — 9.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
77
% held
48.9%
Net QoQ
+2.7M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
88
View
Short & Settlement
Short Interest Rising
Shares short
5.3M
Days to cover
10.3d
Change
+1.1M sh
View
Short Volume
Short vol %
53%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
223
Value
$2.1K
As of
Aug 7, 2026
View
Off-Exchange
Off-exchange %
46.9%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$1.0M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
11
View
Exempt Offerings
Offering
$400.0M
Filed
Feb 28, 2025
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 15, 2026
Last call
Sep 10, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
EIKN -18.4% -13.5% -24.4% -14.5% —
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -17.3% -11.7% -42.2% -14.2% —
Key facts CIK 1861123 CUSIP 282564103 13F (30d) 33 filings 33 filers Visit website Investor relations